SCHEMBL11943815

SCHEMBL11943815

CCOCCOc1c(N2CCN(Cc3c(Cl)cccc3Cl)CC2)cnn(-c2cccc(C)c2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ PAX8 Q06710 1/20 0.46
▸ NPBWR1 P48145 5/20 0.44
▸ MCHR1 Q99705 3/20 0.44
▸ MAPT P10636 2/20 0.40
▸ ALDH1A1 P00352 5/20 0.40
▸ DCTPP1 Q9H773 2/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ PPARG P37231 1/20 0.38
▸ NCOA2 Q15596 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943549 0.93 POLB (0.45) NPBWR1MCHR1MAPTALDH1A1DCTPP1
SCHEMBL11943824 0.91 MAPT (0.40) NPBWR1MCHR1MAPTALDH1A1DCTPP1
SCHEMBL11943814 0.89 NPBWR1 (0.47) NPBWR1MCHR1MAPTALDH1A1DCTPP1
SCHEMBL11943816 0.84 LMNA (0.51) NPBWR1MCHR1MAPTALDH1A1DCTPP1
SCHEMBL14080977 0.83 MAPT (0.52) NPC1RAB9APAX8NPBWR1MAPT
SCHEMBL11943847 0.83 ALDH1A1 (0.43) NPC1RAB9APAX8NPBWR1MCHR1
SCHEMBL11943326 0.82 ALDH1A1 (0.49) NPBWR1MAPTALDH1A1DCTPP1RXFP1
SCHEMBL11943979 0.81 MAPT (0.42) NPC1RAB9APAX8NPBWR1MCHR1
SCHEMBL11945103 0.80 MAPT (0.41) NPC1RAB9APAX8NPBWR1MCHR1
SCHEMBL11945118 0.80 POLB (0.44) NPC1RAB9APAX8NPBWR1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA NPC1 2179/4885RAB9A 4688/4885PAX8 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback